NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma.
NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma.
复制标题
DOI：
10.1097/pas.0000000000001441
复制
发表时间：
2020-06
期刊：
影响因子：
--
通讯作者：
Yoshida A
中科院分区：
文献类型：
--
作者：
Yoshida KI;Machado I;Motoi T;Parafioriti A;Lacambra M;Ichikawa H;Kawai A;Antonescu CR;Yoshida A
NK 3同源框1（NKX 3 -1）是公认的前列腺癌高度敏感和特异的标志物。根据已发表的转录组数据显示EWSR 1-NFATC 2肉瘤中NKX 3 -1 mRNA表达上调，我们探讨了NKX 3 -1免疫组织化学在肉瘤诊断中的应用。我们应用NKX 3 -1免疫组织化学对11例EWSR 1-NFATC 2肉瘤和168例模拟肉瘤进行全组织切片。所有EWSR 1-NFATC 2肉瘤均由均匀的小圆形或卵圆形细胞组成，除1例外，所有肉瘤均至少在纤维/粘液样背景中局部显示典型的巢状、索状或小梁生长模式。常见不同程度的嗜酸性粒细胞浸润。NKX 3 -1在11例EWSR 1-NFATC 2肉瘤中的9例（82%）中表达，通常呈弥漫性，强度中等或较强。所有12例间叶性软骨肉瘤也呈NKX 3 -1阳性，超过一半显示弥漫性染色和中等或强强度。阳性染色仅见于原始小圆细胞成分，而软骨成分大多为阴性。尽管30例骨肉瘤中有1例显示局灶性NKX 3 -1阳性，但所有其余155例受试病例，包括20例尤文肉瘤、20例肌上皮肿瘤、11例骨化性纤维粘液样肿瘤和1例FUS-NFATC 2肉瘤，NKX 3 -1均为阴性。我们的研究提供了EWSR 1-NFATC 2肉瘤和尤文肉瘤可以通过化学方法区分的第一个证据，增加了这些肿瘤表型不同的积累数据。我们认为，NKX 3 -1可能有一个诊断工具，在肉瘤的评估，我们也呼吁注意潜在的陷阱，在使用这个众所周知的标志物前列腺腺癌。
NK3 homeobox 1 (NKX3–1) is widely accepted as a highly sensitive and specific marker for prostatic adenocarcinoma. Prompted by published transcriptome data showing upregulation of NKX3–1 mRNA expression in EWSR1-NFATC2 sarcoma, we explored the utility of NKX3–1 immunohistochemistry in sarcoma diagnosis. We applied NKX3–1 immunohistochemistry to 11 EWSR1-NFATC2 sarcomas and 168 mimics using whole tissue sections. All EWSR1-NFATC2 sarcomas consisted of uniform small round or ovoid cells, all except one showing at least focally the typical growth pattern of nests, cords, or trabeculae within a fibrous/myxoid background. A variable eosinophilic infiltrate was common. NKX3–1 was expressed in 9 out of 11 (82%) EWSR1-NFATC2 sarcomas, often diffuse and of a moderate or strong intensity. All 12 mesenchymal chondrosarcomas tested were also positive for NKX3–1, with over half showing diffuse staining and moderate or strong intensity. The positive staining was seen only in the primitive small round cell component, whereas the cartilaginous component was mostly negative. Although 1 of 30 osteosarcomas showed focal NKX3–1 positivity, all the remaining 155 cases tested, including 20 Ewing sarcomas, 20 myoepithelial tumors, 11 ossifying fibromyxoid tumors, and 1 FUS-NFATC2 sarcoma were negative for NKX3–1. Our study provides the first evidence that EWSR1-NFATC2 sarcoma and Ewing sarcoma could be distinguished immunohistochemically, adding to the accumulating data that these tumors are phenotypically distinct. We suggest that NKX3–1 may have a diagnostic utility in the evaluation of sarcoma and we also call attention to potential pitfalls in the use of this well-known marker of prostatic adenocarcinoma.